Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
 

 

March 30, 2015

Clinical Milestones Abound for PharmaCyte Biotech in 2015

Late last week, PharmaCyte Biotech, Inc. (OTCQB – PMCB - $0.138 – Spec Buy) announced that it was on track to commence clinical trials in the second half of 2015, milestone events that many investors believe will take the Company’s profile and valuation to a new level.   After all, it is no secret that biotech investors tend to gravitate to companies on the cusp of trial initiations.  The reasoning behind these moves is simple. The initiation of any trial, preclinical or late stage, can be a harbinger of potential product development success, depending upon the trial’s outcome. At the least, the commencement of a trial is an affirmation that a biotech company’s technology or approach has merit and may be deserving of future material consideration by peers and investors alike.

With three separate clinical trials for the treatment of advanced pancreatic cancer and the symptoms associated with it as well  slated to begin in a matter of months, PharmaCyte Biotech’s moves are bound to generate a great deal of attention, since it is so rare that a small biotech would launch three separate clinical trials in such short order. 

The most highly anticipated event is a Phase 2b trial in Australia where PharmaCyte Biotech's pancreatic cancer treatment will be compared "head-to-head" with the best available chemotherapy (Abraxane(R) plus gemcitabine) for advanced pancreatic cancer, using its Cell-in-a-Box(R) live cell encapsulation technology, and placing the capsules with the live cells inside them near the site of the cancerous tumor. The patient will be given an inactive cancer drug, ifosfamide, intravenously at one-third the normal dose. When the blood carrying the ifosfamide comes in contact with the encapsulated cells the ifosfamide is converted into its cancer-killing form.

Two additional clinical trials will be conducted in the U.S. by Translational Drug Development (TD2). These trials will determine the effectiveness of PharmaCyte Biotech's treatment in reducing the severe pain that occurs in patients with advanced pancreatic cancer and slowing the accumulation of malignant fluid (ascites) that accompanies the development of pancreatic and other solid cancerous tumors in the abdomen.

Although not seemingly as high profile as the Phase 2b trial, these two trials are landmark events in their own right. These preclinical trials for abdominal cancers using the Company’s platform technology were designed, in part, by the leading authority on pancreatic cancer, Dr. Daniel Von Hoff, and conducted by America’s leading Contract Research Organization that specializes in preclinical and early-mid phase clinical trials in oncology.  Having such distinguished authorities associated with these trials affirms the potential value and efficacy of the Company’s technology and could result in future, fast-tracked clinical trials.

In an era when small biotech companies may only launch one trial a year, having three, high profile, abdominal cancer trial events to look forward to this year could put PharmaCyte Biotech on the map.

For more information, refer to our previous sponsored PMCB Reports, Updates and Hot Topic Articles by visiting www.GoldmanResearch.com/

Senior Analyst: Robert Goldman

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification

I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer

This Microcap Hot Topics Article was prepared for informational purposes only.

Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the Opportunity Research format typically have a higher risk profile, and may offer greater upside. Goldman Small Cap Research was compensated by a third party in the amount of $4000 for a research subscription service and $2500 for a series of articles. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information published by the Company, or other firms. Goldman Small Cap Research relied solely upon information published by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

A Goldman Small Cap Research report or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This publication does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com